Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases

Japanese Journal of Clinical Immunology

Volumn 30, Issue 3, 2007, Pages 165-173

  Kameda, Hideto ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Fibroblast; Interstitial lung disease; Platelet derived growth factor; Rheumatoid arthritis; Systemic sclerosis

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE;

ANIMAL; DRUG EFFECT; HUMAN; INTERSTITIAL LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES, INTERSTITIAL; LUPUS NEPHRITIS; PIPERAZINES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 34548452065     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.165     Document Type: Article

References (52)

1. Heldin C-H, Westermark B.: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283–1316, 1999.
2. Östman A, Heldin C.-H.: Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv Cancer Res 80: 1–38, 2001.
3. Pietras K, Sjöblom T, Rubin K, et al.: PDGF receptors as cancer drug targets. Cancer Cell 3: 439–443, 2003.
4. Cheon H, Sun YK, Yu SJ, et al.: Platelet-derived growth factor-AA increases IL-1β and IL-8 expression and activates NF-κB in rheumatoid fibroblast-like synoviocytes. Scand J Immunol 60: 455–462, 2004.
5. Carroll M, Ohno-Jones S, Tamura S, et al.: CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947–4952, 1997.
6. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561–566, 1996.
7. Dewar AL, Cambareri AC, Zannettino ACW, et al.: Macrophage colony-stimulating factor c-fms is a noveltarget of imatinib. Blood 105: 3127–3132, 2005.
8. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037, 2001.
9. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med; 344: 1038–1042, 2001.
10. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480, 2002.
11. Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481–487, 2002.
12. George D.: Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 28(suppl 17): 27–33, 2001.
13. Choy EH, Panayi GS.: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med 344: 907–916, 2001.
14. Firestein GS, Zvaifler NJ.: How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 46: 298–308, 2002.
15. Muller-Ladner U, Gay RE, Gay S.: Activation of synoviocytes. Curr Opin Rheumatol 12: 186–194, 2000.
16. Yamanishi Y, Firestein GS.: Pathogenesis of rheumatoid arthritis: The role of synoviocytes. Rheum Dis Clin North Am 27: 355–371, 2001.
17. Lafyatis R, Remmers EF, Roberts AB, et al.: Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stmulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 83: 1267–1276, 1989.
18. Muller-Ladner U, Kriegsmann J, Gay RE, et al.: Oncogenes in rheumatoid arthritis. Rheum Dis Clin North Am 21: 675–690, 1995.
19. Imamura F, Aono H, Hasunuma T, et al.: Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum 41: 1979–1986, 1998.
20. Muller-Ladner U, Kriegsmann J, Franklin BN, et al.: Synovial ibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149: 1607–1615, 1996.
21. Kameda H, Risinger JI, Han B-B, et al.: Expression of Gab1 lacking the preckstrin homology domain is associated with neoplastic progression. Mol Cell Biol 21: 6895–6905, 2001.
22. Rubin K, Terracio L, Ronnstrand L, et al.: Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inlammation. Scand J Immunol 27: 285–294, 1988.
23. Remmers EF, Sano H, Wilder RL.: Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 21: 191–199, 1991.
24. Sano H, Engleka K, Mathern P, et al.: Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J Clin Invest 91: 553–565, 1993.
25. Watanabe N, Ando K, Yoshida S, et al.: Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 294: 1121–1129, 2002.
26. Kameda H, Ishigami H, Suzuki M, et al.: Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol 144: 335–341, 2006.
27. Sandler C., Joutsiniemi S, Lindstedt KA, et al.: Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 347: 31–35, 2006.
28. Ando W, Hashimoto J, Nampei A, et al.: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24: 274–282, 2006.
29. Paniagua RT, Sharpe O, Ho PP, et al.: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116: 2633–2642, 2006.
30. Miyachi K, Ihara A, Hankins RW, et al.: Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 22: 329, 2003.
31. Eklund KK, Joensuu H.: Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Ann Med 35: 362–367, 2003.
32. Kameda H, Takeuchi T.: Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets 6: 409–415, 2006.
33. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society Interstitial multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165: 277–304, 2002.
34. Kameda H, Nagasawa H, Ogawa H, et al.: Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32: 1719–1726, 2005.
35. Sontheimer RD, Miyagawa S.: Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J Am Acad Dermatol 48: 797–798, 2003.
36. Daniels CE, Wikes MC, Edens M, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308–1316, 2004.
37. Abdollahi A, Li M, Ping G, et al.: Inhibition of platelet-derived growth factor signaling attenuate pulmonary fibrosis. J Exp Med 201: 925–935, 2005.
38. Aono Y, Nishioka Y, Inayama M, et al.: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171: 1279–1285, 2005.
39. Chaudhary NI, Schnapp A, Park JE.: Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173: 769–776, 2006.
40. Hetzel M, Bachem M, Anders D, et al.: Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung ibroblasts. Lung 183: 225–237, 2005.
41. Matsuda M, Shikata K, Makino H, et al.: Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am J Nephrol 17: 25–31, 1997.
42. Johnson RJ, Raines EW, Floege J, et al.: Inhibition of mesangial cell proliferation and matrix expression in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175: 1413–1416, 1992.
43. Floege J, Ostendorf T, Janssen U, et al.: Novel approach to speciic growth factor inhibition in vivo. Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154: 169–179, 1999.
44. Gilbert RE, Kelly DJ, McKay T, et al.: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324–1332, 2001.
45. Sadanaga A, Nakashima H, Matsutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M.: Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 52: 3987–3996, 2005.
46. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473–2479, 2005.
47. Zoja C., Corna D, Rottoli D, Zanchi C., Abbate M, Remuzzi G.: Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70: 97–103, 2006.
48. Ohba T, Takase Y, Ohhara M, et al.: Thrombin in the synovial luid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet-derived growth factor. J Rheumatol 23: 1505–1511, 1996.
49. Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354: 2667–2676, 2006.
50. Distler JHW, Jungel A, Huber LC, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56: 311–322, 2007.
51. Schermuly RT, Dony E, Ghofrani HA, et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811–2821, 2005.
52. Ghofrani HA, Seeger W, Grimminger F.: Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412–1413, 2005.